You are here: Home » News-CM » Equities » Hot Pursuit
Business Standard

Biocon advances as Mylan enters in pact with Fujifilm

Capital Market 

gained 2.1% to Rs 626 at 10:10 IST on after the company announced that it along with seek to accelerate introduction of biosimilar in

The announcement was made after market hours yesterday, 11 April 2018.

Meanwhile, the Sensex was up 41.53 points, or 0.12% to 33,981.97.

On the BSE, 1.20 lakh shares were traded in the counter so far compared with average daily volumes of 1.07 lakh shares in the past two weeks. The stock had hit a high of Rs 629.55 and a low of Rs 620.65 so far during the day. The stock hit a record high of Rs 657.75 on 24 January 2018. The stock hit a 52-week low of Rs 295 on 25 May 2017.

The large-cap company has equity capital of Rs 300 crore. Face value per share is Rs 5.

announced that the company and have agreed to accelerate introduction of biosimilar in through Mylan's in-licensing arrangement with Kirin Biologics (FKB). FKB's product is at an advanced stage of review and could potentially obtain approval in in the second half of 2018.

Through this arrangement, could commercialize FKB's in (EU) around market formation. retains its economic interest in this arrangement vis-a-vis Mylan in line with its existing global collaboration with Mylan for monoclonal

Biocon's consolidated net profit fell 46.35% to Rs 91.90 crore on 1.96% growth in net sales to Rs 1057.90 crore in Q3 December 2017 over Q3 December 2016.

Biocon is India's largest and fully-integrated, company.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Thu, April 12 2018. 10:25 IST